-
Mashup Score: 6Welcome Home - Gay City: Seattle's LGBTQ Center - 15 day(s) ago
Gay City: Seattle’s LGBTQ Center creates access and connections to LGBTQ-affirming resources, wellness and community.
Source: www.gaycity.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
Binaytara Foundation in Bellevue, Washington, is seeking a passionate and dynamic individual to join our team as the Director of Development.
Source: dickersonbakker.applytojob.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 6अमेरिकाबाट नेपालको क्यान्सर क्षेत्रमा योगदान गरिरहेका डा शाह - 3 month(s) ago
सन् २०१२ देखि उक्त योजनामा काम सुरु भयो। सिभिल अस्पतालमा कार्यरत चिकित्सक, एकजना नर्स र एक प्याथोलोजिस्ट पनि फाउन्डेसनको समन्वय र सहयोगमा युनिभर्सिटी अफ इलिनोइमा पुगेर सिकेर फर्के। यसैगरी फाउन्डेसनकै सहयोग र समन्वयमा अर्का एक चिकित्सकले श्रीलंकाबाट उक्त विषयमा ज्ञानसीप लिए। सन् २०१६ मा डा विनयको सपना पूरा भयो। डा शाहले भने, ‘उपचारका लागि नेपाली दाजुभाइले भारत र सिंगापुर धाउनुपर्ने बाध्यताको अन्त्य गर्ने कार्यमा हामीले पनि धेरथोर सहयोग गर्न पाएकोमा खुशी छौं।’
Source: nepallive.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Summit on Cancer Health Disparities (SCHD24) | Premier Hematology Oncology Conferences - 3 month(s) ago
APRIL 26, 2024All times are listed in Pacific Time (PT)08:00 – 08:15 AM: Welcome 08:15 – 09:30 AM: SESSION I: UNDERSTANDING DISPARITIESSession Co-Chairs: David Aboulafia, MD and Gita Suneja, MD, MS08:15 – 08:35 AM: Keynote speech 08:35 – 09:05 AM: Two case-based presentations (problem description, how it was solved, and the lessons learned)09:05 – 09:30 AM: Panel discussion – Samantha Forney09:30…
Source: education.binayfoundation.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3
Jump to content Bookmark/Search this post
Source: education.binayfoundation.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 10Summit on Cancer Health Disparities (SCHD24) | Premier Hematology Oncology Conferences - 5 month(s) ago
APRIL 26, 2024All times are listed in Pacific Time (PT)08:00 – 08:15 AM: Welcome 08:15 – 09:30 AM: SESSION I: UNDERSTANDING DISPARITIESSession Co-Chairs: David Aboulafia, MD and Gita Suneja, MD, MS08:15 – 08:35 AM: Keynote speech 08:35 – 09:05 AM: Two case-based presentations (problem description, how it was solved, and the lessons learned)09:05 – 09:30 AM: Panel discussion – Samantha Forney09:30…
Source: education.binayfoundation.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2FDA approves Pembrolizumab for resectable NSCLC - 6 month(s) ago
The U.S. Food and Drug Administration approved pembrolizumab for patients with resectable non-small cell lung cancer (NSCLC) tumors ≥4 cm or node positive.
Source: thecancernews.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Bridging Hematologic Cancer Disparities: A Path to Equity | Premier Hematology Oncology Conferences - 6 month(s) ago
Haifaa Abdulhaq, Clinical Professor, UCSF. Director of Hematology, UCSF Fresno. Director of Hematolog/Oncology Fellowship, UCSF Fresno has a financial relationship (Professional Services) with Genentech;. has a financial relationship (Professional Services) with BMS;. has a financial relationship (Professional Services) with…
Source: education.binayfoundation.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5Conference Coverage – Highlights from ESMO 2023 - The Cancer News - 6 month(s) ago
We are thrilled to announce that we will be providing comprehensive coverage of the European Society for Medical Oncology (ESMO) conference taking place in Madrid, Spain from October 20 to 24, 2023. Our dedicated Cancer News Editorial team, including Dr. Lei Deng and contributing expert Dr. Anam Kamal, will be on the ground to bring
Source: thecancernews.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4ESMO 2023 Update – ALINA – The Cancer News - 7 month(s) ago
Thoracic, Head & Neck Medical Oncology In phase 3 ALINA trial, completely resected, stage IB (≥4 cm)–IIIA, ALK+ non-small cell lung cancer (AJCC 7) receive alectinib for 24 months or chemotherapy for up to 4 cycles At 2023 ESMO congress, disease-free survival was reported to be significantly improved in the alectinib arm (HR 0.24) Secondary endpoint of CNS-disease free survival was also improved (HR 0.22) This is the first ALK inhibitor improving disease-free survival in non-small cell lung cancer. An
Source: thecancernews.orgCategories: General Medicine News, Hem/OncsTweet
Amazing talk by on Best Practices in Supporting LGBTQ+ Communities - by Nakita Venus and Elle Brooks, MPH from https://t.co/ltrsEE3MX4 @btfoundation #SCHD24 https://t.co/9SB9mY1ckH